{"id":"NCT02023112","sponsor":"AbbVie","briefTitle":"Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection","officialTitle":"An Open-label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) Co-administered With Ribavirin (RBV) for 12 or 16 Weeks in Treatment-Naïve and Treatment-Experienced Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection With and Without Compensated Cirrhosis (GIFT-II)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-01","primaryCompletion":"2015-04","completion":"2015-09","firstPosted":"2013-12-30","resultsPosted":"2016-05-13","lastUpdate":"2021-07-30"},"enrollment":171,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus"],"interventions":[{"type":"DRUG","name":"ABT-450/r/ABT-267","otherNames":["ABT-267 also known as ombitasvir","ABT-450 also known as paritaprevir","ritonavir also known as Norvir","VIEKIRAX Combination Tablets","VIEKIRA Combination Tablets","Technivie","Qurevo"]},{"type":"DRUG","name":"Ribavirin","otherNames":[]}],"arms":[{"label":"ABT-450/r/ABT-267 plus RBV for 12 weeks","type":"EXPERIMENTAL"},{"label":"ABT-450/r/ABT-267 plus RBV for 16 weeks","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3, randomized, open-label, multicenter study, enrolling non-cirrhotic and cirrhotic subjects. The purpose of this study is to evaluate the efficacy and safety of ABT-450/r/ABT-267 co-administered with weight-based RBV for 12 or 16 weeks in adult chronic HCV genotype 2-infected treatment-naïve and interferon (IFN) treatment-experienced subjects with and without compensated cirrhosis.","primaryOutcome":{"measure":"Percentage of Non-cirrhotic, Treatment-naive Participants in Each Treatment Group With a Sustained Virologic Response 12 Weeks Post-treatment (SVR12)","timeFrame":"12 weeks after last dose of study drug","effectByArm":[{"arm":"ABT-450/r/ABT-267 Plus RBV for 12 Weeks","deltaMin":75,"sd":null},{"arm":"ABT-450/r/ABT-267 Plus RBV for 16 Weeks","deltaMin":91.5,"sd":null}],"pValues":[{"comp":"OG001","p":null},{"comp":"OG000","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28536999"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":80},"commonTop":["ANAEMIA","BLOOD BILIRUBIN INCREASED","NASOPHARYNGITIS","HEADACHE","PRURITUS"]}}